Levetiracetam Stada Arzneimittel Ag (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which regulates neurotransmitter release. This binding modulates vesicle exocytosis, reducing the release of excitatory neurotransmitters and stabilising neuronal firing, thereby decreasing the likelihood of seizure propagation.

The appropriate dose of Levetiracetam is set by the prescribing clinician based on the patient’s age, weight, renal function, seizure type, and response to therapy. Dosage adjustments may be required for patients with impaired kidney function or when used in combination with other antiepileptic drugs.

Levetiracetam’s pregnancy category is listed as unknown, meaning that potential risks cannot be ruled out. It should only be used during pregnancy or lactation if the expected benefit to the mother outweighs possible risks to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with many older antiepileptics, Levetiracetam has a relatively simple pharmacokinetic profile, few drug‑enzyme interactions, and does not require routine therapeutic drug monitoring. However, it may be associated with behavioral side effects that are less common with drugs such as carbamazepine or valproate.

Levetiracetam tablets should be stored at room temperature below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Levetiracetam is taken orally, usually as a tablet swallowed whole with water. It can be taken with or without food. The exact schedule—once, twice or three times daily—depends on the prescriber’s instructions and the individual patient’s therapeutic needs.

Serious adverse events include severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome, significant mood alterations like depression or suicidal thoughts, and rare blood disorders such as neutropenia or thrombocytopenia. Patients should seek immediate medical attention if they notice rash, mood changes, or signs of infection.

Levetiracetam is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Caution is advised for patients with severe renal impairment who may require dose reduction, and for those with a history of serious psychiatric disorders, as the medication can exacerbate mood symptoms.